SBS Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.…
Industry Peers
Medical DevicesKey Statistics
About Stratec (ETR: SBS)
›
Stratec (ETR: SBS) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,352 employees.
The shares were at 28.60 EUR on 19 November 2026, up 31.8% over 52 weeks. Its 52-week range is 16.30 EUR to 29.85 EUR: the price is 4.2% below the high and 75.5% above the low.
Its market capitalisation is 347.66M EUR. It pays a dividend yielding 2.22% (it pays out 47% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
Stratec reports return on equity of -0.1%, an operating margin of -10.7% and revenue down 8.1% year over year.
Its debt exceeds its cash by 88.90M EUR, a debt-to-equity ratio of 0.56. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 33.20 EUR is 16.1% above the current price. The next earnings report is expected on 27 April 2027.